Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453154 | 0.75 | GPR119 (0.48) | GPR119KDM4EPKMMMP13MMP1 | |
| SCHEMBL1155958 | 0.75 | GPR119 (0.50) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL31066437 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL968159 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155802 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155865 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155836 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155839 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155840 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 | |
| SCHEMBL1155805 | 0.74 | GPR119 (0.54) | GPR119USP30KDM4EPKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | GPR119 2776/4885USP30 4033/4885KDM4E 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.